G
GenSciences
Develops drugs that focus on underserved illnesses like hemophilia, metabolic diseases, and anti-tumor fields
About GenSciences
GeneScience Pharmaceuticals Co., Ltd. (GenSci) is a biopharmaceutical company established in 1996, operating as a key subsidiary of the publicly traded Changchun High-Tech Industries Group. The company was co-founded by Dr. Lei Jin, who currently serves as CEO and Chief Scientist. Dr. Jin earned a Ph.D. from the University of California and gained experience at the U.S. biomedical firm Genentech before returning to China in 1995 to establish the company with funding from Changchun High and New Tech. Headquartered in the Changchun High-Tech Development Zone, a national hub for biomedicine, GenSci leverages genetic engineering and recombinant technology to develop and manufacture its products.
GenSci's business model is centered on the research, development, manufacturing, and commercialization of genetically engineered pharmaceuticals. The company primarily serves markets in pediatric health, women's health, and wound healing, with strategic expansion into endocrinology, immunology, and oncology. A significant milestone was the 1998 launch of Jintropin®, the first recombinant human growth hormone (rhGH) in China. This product line has since expanded, making GenSci a global provider in the rhGH market. Another key achievement includes the 2014 release of Jintrolong®, recognized as the world's first long-acting growth hormone injection. The company's R&D efforts are substantial, with an investment of over RMB 2.4 billion in 2023, representing 16.48% of its revenue. GenSci has also established a global innovation hub in Shanghai to accelerate its R&D pipeline.
The company's product portfolio is diverse, featuring a range of biologics and innovative biogenerics. Core products include the Jintropin® and Jintrolong® brands of somatropin for treating growth hormone deficiencies in both pediatric and adult patients. Other notable products are Genfulin® (Molgramostim Gel) for wound healing and tissue repair, and Jinfollin®, a Follitropin injection for women's health. These products address conditions such as pediatric growth failure, Turner syndrome, and adult growth hormone deficiency. GenSci markets its products through a combination of direct sales and partnerships, with a growing global presence in regions like Southeast Asia and Central America.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1996
- Headquarters
- Changchun, China
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 47.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2021 | $100M | $400M | IDG Capital · New Alliance Capital · Haitong Securities · Efung Capital | — |
| SERIES AOther financing | Mar 2021 | $23M | $92M | New Alliance Capital · Huaige Capital · IDG Capital | — |
Growth signals
Latest recorded traffic for GenSciences is 2.6K monthly website visits, up 242.1% over the last three months. GenSciences's team grew 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GenSciences in the Changchun ecosystem
The GenSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
IDG Capital
New Alliance Capital- HSHaitong Securities
- ECEfung Capital
- HMHaurong Rongde Asset Management
- HCHuaige Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GenSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GenSciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










